Barbara McAneny on How the Repeal of the ACA Without a Replacement Threatens the Health of Patients and the Success of Community PracticesFebruary 15th 2017
In this interview we discuss how the ACA, which was passed in 2010, changed the way oncologists treat their patients, and how a repeal of the law would affect patients’ access to care.
Accelerated Partial Breast Irradiation for Breast Cancer: Not Ready for Routine UseFebruary 15th 2017
We know that breast cancer represents a spectrum of diseases, with variation in prognosis, and that RT can range from highly complex treatments to the breast and regional lymph nodes, to complete avoidance of radiation.
Accelerated Partial Breast Irradiation for Breast Cancer: An Innovative Option for Selected Early-Stage CancersFebruary 15th 2017
To paraphrase a deep philosophical question: if an important, long-awaited phase III prospective randomized trial from Europe is published and no one pays attention, does it make a sound?
Novel and Expanded Oncology Drug Approvals of 2016-PART 1: New Options in Solid Tumor ManagementFebruary 15th 2017
This article focuses on the new agents and indications that emerged in 2016 for solid tumor treatment. We review the drug indications, mechanisms of action, pivotal trial data, pertinent toxicities, use in special populations, and the appropriate clinical contexts for treatment planning.
Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic MalignanciesFebruary 15th 2017
This article reviews newly approved drugs for hematologic malignancies: their indications, mechanisms of action, accompanying pivotal trial data, pertinent toxicities, use in special populations, and appropriate clinical context.